Date: February 05, 2025
Ref. No.: KDL/SE/100/2025-26

To,	To,
BSE Limited	**National Stock Exchange of India Limited**
Corporate Relationship Department	Exchange Plaza, Plot No. C-1, Block G,
25th Floor, Phiroze Jeejeebhoy Towers	Bandra Kurla Complex, Bandra (East)
Dalal Street, Mumbai- 400001	Mumbai – 400051
Scrip Code: 543328	**NSE Symbol:** KRSNAA

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation.

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2025.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For Krsnaa Diagnostics Limited

Sujoy Sudipta Bose
Digitally signed by Sujoy Sudipta Bose
Date: 2026.02.05 20:09:15 +05'30'

Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above

krsnaa DIAGNOSTICS
LET'S DO GOOD...

Q3 & 9M FY2026
Results Presentation

One of **INDIA'S LARGEST** Integrated Diagnostic Service Provider

Disclaimer

This presentation contains statements that are "forward-looking statements", including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements pertaining to Krsnaa Diagnostics' future business developments and economic performance. While these forward-looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macroeconomic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward-looking statements to reflect future/ likely events or circumstances.

Krsnaa Diagnostics Limited

LET'S DO GOOD...

Krsnaa Diagnostics At a Glance

190
CT/ MRI Centres

4,000+
Patient Collection Centres

81 Million+
Patients Served Since Inception

140
Pathology Labs

18 States/UT
Presence in India

Krsnaa Diagnostics is one of the **fastest growing and Integrated diagnostic service provider** which includes radiology, pathology and tele-radiology

Provides **quality** and inclusive diagnostic services at **affordable rates** across various segments with a focus on Public Private Partnership model

One of India's largest NABH accredited tele-radiology reporting hub with inherent capability & capacity to process X-rays, CT scans and MRI scans, serving patients at remotest locations

The workforce comprises **350+ radiologists**, **120+ pathologists**, and **3,000+ qualified professionals,** including clinicians, technicians and operators

Retail Dynamics









"Y-o-Y Retail Business Revenue Increased By ~8x"

9MFY26 Financial Performance

Particulars	9M FY26	9M FY25	Growth
Revenue	5,802	5,311	9%
EBIDTA	1,600	1,416	13%
EBIDTA Margin	28%	27%	92 bps
PAT	597	569	5%
PAT Margin	10%	11%	(43 bps)

Particulars	9M FY26	9M FY25	Growth
EPS	18.2	17.3	5%
No. of Patient Served	15	14.5	3%
No. of Test performed	45.4	46.9	(3%)
NABL Accreditation (Pathology lab)	57	49	16%
NABH Accreditation (Radiology Centre)	49	26	88%

Note: 1. Financial results of the Company are best monitored on annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter
2. EBIDTA is excluding CSR & ESOP, INR in mn except EPS, NABL & NABH

Q3FY26 Financial Performance

Metric	Q3FY26	Q3FY25	Change
Revenue from operation	1,812	1,745	▲ 4%
Normalised EBIDTA	484	465	▲ 4%
Normalised PAT	168	169	▽ 1%
Normalised EBIDTA Margin	27%	27%	▲ 3bps
Normalised PAT Margin	9%	10%	▽ 44bps
No. of Patient Served	4.6	4.6	▲ 1%

Note: 1. Financial results of the Company are best monitored on annual basis, as there is a certain level of cyclicity in business, and specific quarter performance may be impacted by specific events in that quarter

2. Normalized EBITDA excludes CSR, ESOP, and operational expenses incurred due to the ongoing implementation of the Rajasthan pathology project and the change in labour law aggregating Rs.10 mn. wherein revenue is not proportionate to these expenses. Normalized PAT excludes the above-mentioned expenses

Launch of 1st Apulki Healthcare Hospital

01 1st PPP Cancer and cardiac care hospital in india

02 150 beds in Association with Pune Municipal Corporation

03 All cancer treatment at CGHS rates under cash and carry model

04 Approval to operationalise 4 more hospitals with capacity of 600 beds

05 Designed on same PPP principles that have scaled Krsnaa Diagnostics platform nationally

Facilities Under Apulki Healthcare Hospital

LINAC

160 Slice Cardiac CT

PET CT

Facilities Under Apulki Healthcare Hospital

Dexa

X-Ray

Mammography

Q3 FY26 – Centre Growth

Krsnaa Diagnostics
LET'S DO GOOD...

Radiology

CT Centre



MRI Centre



Tele- Radiology Centre



> Upon completion of our existing order book, we will have **200+ CT/MRI** centres, cementing our position as one of **Asia's Largest Radiology Players.**

Pathology

Reference Lab



Satellite Lab



Collection Centres



> The Rajasthan project will grow our network to **49** Reference Labs, **249** Satellite Labs & **5,000+** Collection Centres — making us **India's Deeply Rooted** and **Widely Accessible** Pathology Service Provider.

Competitive Advantages

Driving Excellence Through Quality- **INDIA'S 1ST**

ACR Recognized Company

CAP Accredited Lab at Government Facility

NABH Accredited Tele-Radiology Hub

Service Excellence Pioneers of Indian Diagnostic Industry

Driving Excellence Through Quality

Quality Multiplied: The Power of 100+ Accreditations

57

National Accreditation for Board of testing's & Calibration Laboratories

49

National Accreditation Board for Hospitals & Healthcare Providers

We are committed to delivering superior quality as our benchmark and proudly served **~4.6 mn patients** in Q3 FY26, driven by our continuous focus on excellence.

Building India's National Diagnostics Infrastructure

Krsnaa DIAGNOSTICS
LET'S DO GOOD...

The only listed company in PPP (Public Private Partnership) space with bid win ratio of 75%+

18 states and union territories with penetration till tier-II and tier-III towns

~81 Mn+ patients served since inception

Integrated diagnostic services available for 24/7 and 365 days, Radiology, Pathology, and Teleradiology

Quality diagnostic services at most affordable prices (50-70% lower than the peers)

Operationalizing retail presence in 4 states

Krsnaa has redefined what's possible in diagnostics — proving that we can deliver radiology services at prices up to 50-70% lower than market, in a **capital-intensive business, and still generate margins** at par with the industry's best. **This isn't a low-price government contract story — it's a high-efficiency, high-impact model built to scale.**

Our Pricing - "Everyone Can Afford"

Segment	Test	Competition 1	Competition 2	Competition 3	Krsnaa	% lower from competitors
Radiology	CT Brain	4,500	4,500	3,500	880	(75)%
Radiology	MRI Brain	8,000	8,250	7,000	1,340	(81)%
Pathology	CBC	250	250	200	37	(82)%
Pathology	Blood Sugar	85	80	70	20	(71)%
Pathology	Thyroid	500	550	550	55	(90)%
Pathology	Vitamin D	1,500	1,250	1,450	153	(89)%
Pathology	Vitamin B12	1,000	1,100	1,300	69	(95)%
Pathology	HbA1C	550	440	400	49	(88)%

By offering services at **over 50-70% below** market rates, Krsnaa Diagnostics is expanding access to millions across India — and still growing faster than the industry, proving that **scale, efficiency, and impact can go hand in hand.**

Note:
Amounts are in INR.
Above mentioned examples from our comprehensive test lists for illustration purpose only and referenced from publicly available information

Presence - PAN India

Well Diversified Regional Revenue Mix





India map for representation only, not to scale

Financial Performance

Consolidated Financial Performance

Krsnaa Diagnostics
LET'S DO GOOD...

In mn

Particulars	Q3 FY 26		Q3 FY 25		Q2 FY 26		9M FY 26		9M FY 25	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	**1,812**		**1,745**		**2,060**		**5,802**		**5,311**	
Expenses										
Cost of Material Consumed	391	22%	399	23%	481	23%	1,347	23%	1,277	24%
Employee benefits expense	356	20%	348	20%	348	17%	1,053	18%	1,008	19%
Fees to hospitals and others	150	8%	136	8%	170	8%	474	8%	433	8%
Other expenses	440	24%	397	23%	459	22%	1,327	23%	1,177	22%
Total Expenses	1,337	74%	1,280	73%	1,458	71%	4,201	72%	3,895	73%
Share of Profit/ (loss) of Associate	(1)	0%	-	-	0.1	-	(1)	0%	-	-
EBITDA Before CSR & ESOP	**474**	**26%**	**466**	**27%**	**602**	**29%**	**1,600**	**28%**	**1,416**	**27%**
CSR and ESOP	10	1%	15	1%	10	1%	31	1%	45	1%
EBITDA	**464**	**26%**	**451**	**26%**	**592**	**29%**	**1,569**	**27%**	**1,371**	**26%**
Less: Finance costs	78	4%	61	4%	82	4%	223	4%	178	3%
Less: Depreciation	227	13%	227	13%	236	11%	679	12%	664	13%
Add: Other income	38	2%	92	5%	42	2%	119	2%	211	4%
PBT	**197**	**11%**	**255**	**15%**	**316**	**15%**	**786**	**14%**	**741**	**14%**
Tax	44	2%	61	4%	77	4%	190	3%	172	3%
PAT	**152**	**8%**	**194**	**11%**	**239**	**12%**	**597**	**10%**	**569**	**11%**

krsnaa DIAGNOSTICS
LET'S DO GOOD...

For further information please contact

Krsnaa Diagnostics

Vivek Jain, Head- Investor Relations

head.investor@krsnaa.in

Contact: +91 74107 00645

https://krsnaadiagnostics.com